ApoA1 antibody
- Known as:
- ApoA1 (anti-)
- Catalog number:
- 10-1839
- Product Quantity:
- 200 ul
- Category:
- -
- Supplier:
- Fitzgerald
- Gene target:
- ApoA1 antibody
Related genes to: ApoA1 antibody
- Gene:
- APOA1 NIH gene
- Name:
- apolipoprotein A1
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 11q23.3
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2019-04-23
Related products to: ApoA1 antibody
Related articles to: ApoA1 antibody
- - Source: PubMed
Publication date: 2026/03/04
Lu ZhimingLin QiyiChen Jinian - Hepatocellular carcinoma (HCC) is a cancer with high incidence and mortality rate. Although immune checkpoint inhibitors (ICIs) improved survival outcomes for HCC patients, limited objective response rate highlights the urgency of investigating determinants of immunotherapy. Here, we explore HCC resistance mechanisms following neoadjuvant αPD-1 immunotherapy by constructing a comprehensive multi-modal single-cell transcriptomic atlas consisting of 14 HCC patients treated with αPD-1 from our cohort (ClinicalTrials.gov ID: NCT06571396) and 60 external HCC cases with heterogeneous treatment backgrounds. Supervised by clinical outcomes of our cohort, we identify positive and negative regulators of immunotherapy within the tumor immune microenvironment (TIME), especially lipid-associated macrophages (LAM) with increased lipid metabolic state in non-responders and characterized by C1QA, FABP1, and APOA1 expression. We further show the presence, exogenous inducements and immunosuppressive functions of LAM, along with regulation strategies of its lipid-associated condition, including lycopene and chiglitazar. Furthermore, we construct interaction networks of immune regulators across responders and non-responders, showing distinct ligand-receptor landscapes with intervention targets. We reveal the TIME components including immunosuppressive LAMs that influence immunotherapy outcomes, thus providing evidence and insights for exploring immune landscape and therapeutic strategies for HCC immunotherapy. ClinicalTrials.gov ID: NCT06571396. - Source: PubMed
Publication date: 2026/07/31
Peng ShengxuanLiu ChangLong JunyuTian JinchengLi HanLu DonghaiCao QihangZhang DaolinHe QiaoJia JisenWang YuxuanDong ZhaoruZhao HaitaoZhao LeiWang DongxuLi Tao - This study aimed to investigate whether the systemic inflammation response index (SIRI) acts as a mediator between the apolipoprotein B/A1 ratio and atrial fibrillation, and assess the combined discriminative ability of the two indicators for identifying AF. - Source: PubMed
Publication date: 2026/08/13
Zheng ChenyangJia MeixueNing Bin - Opium, traditionally used for its analgesic and sedative properties, has been widely consumed. Given the conflicting evidence regarding its association with lipid profiles, the present study was conducted to investigate the association between opium consumption and lipid profile parameters. - Source: PubMed
Publication date: 2026/08/26
Fard Fatemeh Zahra GafuoriMohammadi YaserRezaei MaryamRiahi Seyed Mohammad - Labour dystocia (LAD) in sows is a common reproductive disorder that reduces piglet survival rates and increases the number of stillbirths, causing substantial economic losses to pig farms. However, the genetic basis of LAD remains elusive. Herein, we performed a single-breed genome-wide association study (GWAS) for LAD using imputed whole-genome sequence data from 3263 sows (487 Landrace and 2776 Yorkshire). - Source: PubMed
Publication date: 2026/08/09
Zhou ShenpingHan JinyiYuan JingliQiao ChuanminChao ZheDuan DongdongLi MengyuWang ZhenyuTan ShuyiLi XinjianXin Wenshui